The Effect of Esmolol Versus Dexmedetomidine on Postoperative Pain Control in Endoscopic Sinus Surgery: A Randomized Trial.

Q2 Medicine
Anesthesiology and Pain Medicine Pub Date : 2025-05-26 eCollection Date: 2025-06-30 DOI:10.5812/aapm-158065
Amany Faheem Omara, Alaa Mohammed Abo Hagar, Asmaa Fawzy Amer
{"title":"The Effect of Esmolol Versus Dexmedetomidine on Postoperative Pain Control in Endoscopic Sinus Surgery: A Randomized Trial.","authors":"Amany Faheem Omara, Alaa Mohammed Abo Hagar, Asmaa Fawzy Amer","doi":"10.5812/aapm-158065","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Functional endoscopic sinus surgery (FESS) is the cornerstone of treatment for nasal pathology.</p><p><strong>Objectives: </strong>This randomized study compares the ability of preoperative and intraoperative esmolol and dexmedetomidine to induce postoperative analgesia and sedation.</p><p><strong>Methods: </strong>Seventy ASA I and II patients, of either sex, scheduled for FESS, were divided into two groups: The esmolol group (group E) received an intravenous bolus dose of 0.5 mg/kg prior to the induction of anesthesia, followed by 0.05 mg/kg/min and stopped immediately upon extubation, while the dexmedetomidine group (group D) received 1 µg/kg of dexmedetomidine over 10 minutes, immediately before the induction of anesthesia, followed by a 0.5 µg/kg/hour infusion after induction and stopped immediately upon extubation. Mean arterial pressure and heart rate were monitored before induction, before and after intubation, and then every 5 to 30 minutes, as well as every 10 minutes until 90 minutes following the commencement of the IV medication infusion. The sedation level was assessed using the Ramsay sedation scale at 15, 30, and 60 minutes postoperatively. Pain scores were evaluated in the recovery room (on arrival and then 15 minutes, 30 minutes, and 1 hour later) and at 2 hours, 6 hours, 12 hours, and 24 hours. The length of the procedure, the degree of bleeding during the intervention, and the occurrence of any adverse effects were documented. Categorical data were summarized as counts and percentages and compared by the chi-square test. Continuous data were assessed for normality using the Shapiro-Wilk test. The Student's <i>t</i>-test was used for quantitative variables that are normally distributed, whereas the Mann-Whitney test was used for quantitative variables that are not.</p><p><strong>Results: </strong>According to our findings, both esmolol and dexmedetomidine were safe and beneficial in reducing blood loss during FESS, promoting optimal surgical field quality, and improving surgical field visibility. Dexmedetomidine was far more effective in providing postoperative sedation, reducing the need for opioids, and delaying the initial need for postoperative analgesia.</p><p><strong>Conclusions: </strong>It was discovered that esmolol and dexmedetomidine both provided superior surgical field, less nasal hemorrhage, and more successful results. Dexmedetomidine caused effective sedation and a reduced need for analgesics.</p>","PeriodicalId":7841,"journal":{"name":"Anesthesiology and Pain Medicine","volume":"15 3","pages":"e158065"},"PeriodicalIF":0.0000,"publicationDate":"2025-05-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12297030/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Anesthesiology and Pain Medicine","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5812/aapm-158065","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/6/30 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Functional endoscopic sinus surgery (FESS) is the cornerstone of treatment for nasal pathology.

Objectives: This randomized study compares the ability of preoperative and intraoperative esmolol and dexmedetomidine to induce postoperative analgesia and sedation.

Methods: Seventy ASA I and II patients, of either sex, scheduled for FESS, were divided into two groups: The esmolol group (group E) received an intravenous bolus dose of 0.5 mg/kg prior to the induction of anesthesia, followed by 0.05 mg/kg/min and stopped immediately upon extubation, while the dexmedetomidine group (group D) received 1 µg/kg of dexmedetomidine over 10 minutes, immediately before the induction of anesthesia, followed by a 0.5 µg/kg/hour infusion after induction and stopped immediately upon extubation. Mean arterial pressure and heart rate were monitored before induction, before and after intubation, and then every 5 to 30 minutes, as well as every 10 minutes until 90 minutes following the commencement of the IV medication infusion. The sedation level was assessed using the Ramsay sedation scale at 15, 30, and 60 minutes postoperatively. Pain scores were evaluated in the recovery room (on arrival and then 15 minutes, 30 minutes, and 1 hour later) and at 2 hours, 6 hours, 12 hours, and 24 hours. The length of the procedure, the degree of bleeding during the intervention, and the occurrence of any adverse effects were documented. Categorical data were summarized as counts and percentages and compared by the chi-square test. Continuous data were assessed for normality using the Shapiro-Wilk test. The Student's t-test was used for quantitative variables that are normally distributed, whereas the Mann-Whitney test was used for quantitative variables that are not.

Results: According to our findings, both esmolol and dexmedetomidine were safe and beneficial in reducing blood loss during FESS, promoting optimal surgical field quality, and improving surgical field visibility. Dexmedetomidine was far more effective in providing postoperative sedation, reducing the need for opioids, and delaying the initial need for postoperative analgesia.

Conclusions: It was discovered that esmolol and dexmedetomidine both provided superior surgical field, less nasal hemorrhage, and more successful results. Dexmedetomidine caused effective sedation and a reduced need for analgesics.

艾司洛尔与右美托咪定对内镜鼻窦手术术后疼痛控制的影响:一项随机试验。
背景:功能性内窥镜鼻窦手术(FESS)是鼻病理治疗的基石。目的:这项随机研究比较术前和术中艾司洛尔和右美托咪定诱导术后镇痛和镇静的能力。方法:ASA I、II期患者70例,男女均可,分为两组:艾司洛尔组(E组)在麻醉诱导前静脉滴注剂量0.5 mg/kg,随后滴注剂量0.05 mg/kg/min,拔管后立即停药;右美托咪定组(D组)在麻醉诱导前10分钟内滴注右美托咪定1µg/kg,诱导后滴注0.5µg/kg/h,拔管后立即停药。在诱导前、插管前、插管后监测平均动脉压和心率,然后每5 ~ 30分钟监测一次,开始静脉输注药物后每10分钟监测一次,直至90分钟。术后15分钟、30分钟、60分钟采用Ramsay镇静量表评估镇静水平。在恢复室(到达时,15分钟,30分钟和1小时后)以及2小时,6小时,12小时和24小时评估疼痛评分。记录手术时间、干预期间出血的程度以及任何不良反应的发生。分类数据汇总为计数和百分比,并用卡方检验进行比较。使用Shapiro-Wilk检验评估连续数据的正态性。学生t检验用于正态分布的定量变量,而Mann-Whitney检验用于非正态分布的定量变量。结果:根据我们的研究结果,艾司洛尔和右美托咪定都是安全的,有利于减少FESS术中出血量,促进最佳手术野质量,提高手术野能见度。右美托咪定在提供术后镇静、减少对阿片类药物的需求和延迟最初的术后镇痛需求方面要有效得多。结论:艾司洛尔和右美托咪定均能提供更好的手术范围,更少的鼻出血,更成功的治疗效果。右美托咪定引起有效镇静,减少了对镇痛药的需求。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Anesthesiology and Pain Medicine
Anesthesiology and Pain Medicine Medicine-Anesthesiology and Pain Medicine
CiteScore
4.60
自引率
0.00%
发文量
49
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信